Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children <5 in Asia

被引:32
作者
Burnett, Eleanor [1 ]
Tate, Jacqueline E. [2 ]
Kirkwood, Carl D. [3 ]
Nelson, E. Anthony S. [4 ]
Santosham, Mathuram [5 ]
Steele, A. Duncan [3 ]
Parashar, Umesh D. [2 ]
机构
[1] CDC Fdn, Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA
[2] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA
[3] Bill & Melinda Gates Fdn, Enter & Diarrheal Dis Global Hlth, Seattle, WA USA
[4] Prince Wales Hosp, Dept Paediat, Hong Kong, Hong Kong, Peoples R China
[5] Johns Hopkins Univ, Int Hlth, Baltimore, MD USA
关键词
Rotavirus vaccines; rotavirus; diarrhea; Asia; routine vaccination; mortality; POPULATION-BASED SURVEILLANCE; HONG-KONG CHILDREN; PLACEBO-CONTROLLED TRIAL; DISEASE BURDEN; RIX4414; EFFICACY; ECONOMIC BURDEN; GASTROENTERITIS; EPIDEMIOLOGY; AGE; SAFETY;
D O I
10.1080/14760584.2018.1443008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Of the 215,000 global deaths from rotavirus estimated in 2013, 41% occur in Asian countries. However, despite a recommendation for global rotavirus vaccination since 2009, only eight countries in Asia have introduced the rotavirus vaccine into their national immunization program as of September 2017. To help policy makers assess the potential value of vaccination, we projected the reduction in rotavirus hospitalizations and deaths following a hypothetical national introduction of rotavirus vaccines in all countries in Asia using data on national-level rotavirus mortality, <5 population, rotavirus hospitalizations rates, routine vaccination coverage, and vaccine effectiveness.Methods: To quantify uncertainty, we generated 1,000 simulations of these inputs.Results: Our model predicted 710,000 fewer rotavirus hospitalizations, a 49% decrease from the 1,452,000 baseline hospitalizations and 35,000 fewer rotavirus deaths, a 40% decrease from the 88,000 baseline deaths if all 43 Asian countries had introduced rotavirus vaccine. Similar reductions were projected in subanalyses by vaccine introduction status, subregion, and birth cohort size.Conclusion: Rotavirus vaccines will substantially reduce morbidity and mortality due to rotavirus infections in Asia.
引用
收藏
页码:453 / 460
页数:8
相关论文
共 56 条
  • [21] The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
    Hutton, Brian
    Salanti, Georgia
    Caldwell, Deborah M.
    Chaimani, Anna
    Schmid, Christopher H.
    Cameron, Chris
    Ioannidis, John P. A.
    Straus, Sharon
    Thorlund, Kristian
    Jansen, Jeroen P.
    Mulrow, Cynthia
    Catala-Lopez, Ferran
    Gotzsche, Peter C.
    Dickersin, Kay
    Boutron, Isabelle
    Altman, Douglas G.
    Moher, David
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 162 (11) : 777 - 784
  • [22] Isanaka S, 2017, NEW ENGL J MED, V376, P1121, DOI [10.1056/NEJMoa1609462, 10.1056/nejmoa1609462]
  • [23] Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006-2016
    Jonesteller, Christine L.
    Burnett, Eleanor
    Yen, Catherine
    Tate, Jacqueline E.
    Parashar, Umesh D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2017, 65 (05) : 840 - 850
  • [24] Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: A systematic review
    Kawai, Kosuke
    O'Brien, Megan A.
    Goveia, Michelle G.
    Mast, T. Christopher
    El Khoury, Antoine C.
    [J]. VACCINE, 2012, 30 (07) : 1244 - 1254
  • [25] Kirkwood CD, 2017, VACCINE
  • [26] Epidemiology and burden of rotavirus disease in Central Asia
    Latipov, Renat
    Utegenova, Elmira
    Kuatbayeva, Aynagul
    Kasymbekova, Kaliya
    Abdykarimov, Sabyrjan
    Juraev, Rivojiddin
    Ismailov, Umid
    Flem, Elmira
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (07) : E464 - E469
  • [27] Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: A randomized, controlled trial
    Lau, Yu-Lung
    Nelson, E. Anthony S.
    Poon, Kin-Hung
    Chan, Paul K. S.
    Chiu, Susan
    Sung, Rita
    Leung, Chi Wai
    Ng, Daniel
    Ma, Yee Man
    Chan, Desmond
    Lee, Tsz Leung
    Tang, Joyce
    Kwan, Yat Wah
    Ip, Patricia
    Ho, Marco
    Fung, Lai-Wah Eva
    Tang, Haiwen
    Suryakiran, P. V.
    Han, Htay Htay
    Bock, Hans
    [J]. VACCINE, 2013, 31 (18) : 2253 - 2259
  • [28] Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam
    Le, Luan T.
    Nguyen, Trang V.
    Nguyen, Phuong M.
    Huong, Nguyen T.
    Huong, Ngo T.
    Huong, Nguyen T. M.
    Hanh, Tran B.
    Ha, Dang N.
    Anh, Dang D.
    Gentsch, Jon R.
    Wang, Yuhuan
    Esona, Mathew D.
    Glass, Roger I.
    Steele, A. Duncan
    Kilgore, Paul E.
    Man, Nguyen V.
    Jiang, Baoming
    Hien, Nguyen D.
    [J]. VACCINE, 2009, 27 : F130 - F138
  • [29] Human rotavirus vaccine (RIX4414) efficacy in the first two years of life A randomized, placebo-controlled trial in China
    Li, Rong-cheng
    Huang, Teng
    Li, Yanping
    Luo, Dong
    Tao, Junhui
    Fu, Botao
    Si, Guoai
    Nong, Yi
    Mo, Zhaojun
    Liao, XueYan
    Luan, Ivy
    Tang, Haiwen
    Rathi, Niraj
    Karkada, Naveen
    Han, Htay Htay
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (01) : 11 - 18
  • [30] The Hidden Health and Economic Burden of Rotavirus Gastroenteritis in Malaysia An Estimation Using Multiple Data Sources
    Loganathan, Tharani
    Ng, Chiu-Wan
    Lee, Way-Seah
    Jit, Mark
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (06) : 601 - 606